Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients – "En route for eradication"?. Issue 3 (September 2017)

• Record Type: Journal Article
• Authors: Cotte, L.; Chidiac, C.; Ferry, T.; Ader, F.; Biron, F.; Boibieux, A.; Miailhes, P.; Perpoint, T.; Schlienger, I.; Lippmann, J.; Braun, E.; Koffi, J.; Longuet, C.; Guéripel, V.; Augustin-Normand, C.; Brochier, C.; Degroodt, S.; Pugliese, P.; Ceppi, C.; Cua, E.; Cottalorda, J.; Courjon, J.; Dellamonica, P.; Demonchy, E.; De Monte, A.; Durant, J.; Etienne, C.; Ferrando, S.; Fuzibet, J.G.; Garraffo, R.; Joulie, A.; Risso, K.; Mondain, V.; Naqvi, A.; Oran, N.; Perbost, I.; Pillet, S.; Prouvost-Keller, B.; Wehrlen-Pugliese, S.; Rosenthal, E.; Sausse, S.; Rio, V.; Roger, P.M.; Brégigeon, S.; Faucher, O.; Obry-Roguet, V.; Orticoni, M.; Soavi, M.J.; Geneau de Lamarlière, P.; Laroche, H.; Ressiot, E.; Carta, M.; Ducassou, M.J.; Jacquet, I.; Gallie, S.; Galinier, A.; Ritleng, A.S.; Ivanova, A.; Blanco-Betancourt, C.; Lions, C.; Debreux, C.; Obry-Roguet, V.; Poizot-Martin, I.; Agher, R.; Katlama, C.; Valantin, M.A.; Duvivier, C.; Lortholary, O.; Lanternier, F.; Charlier, C.; Rouzaud, C.; Aguilar, C.; Henry, B.; Lebeaux, D.; Cessot, G.; Gergely, A.; Consigny, P.H.; Touam, F.; Louisin, C.; Alvarez, M.; Biezunski, N.; Cuzin, L.; Debard, A.; Delobel, P.; Delpierre, C.; Fourcade, C.; Marchou, B.; Martin-Blondel, G.; Porte, M.; Mularczyk, M.; Garipuy, D.; Saune, K.; Lepain, I.; Marcel, M.; Puntis, E.; Atoui, N.; Casanova, M.L.; Faucherre, V.; Jacquet, J.M.; Le Moing, V.; Makinson, A.; Merle De Boever, C.; Montoya-Ferrer, A.; Psomas, C.; Reynes, J.; Raffi, F.; Allavena, C.; Billaud, E.; Biron, C.; Bonnet, B.; Bouchez, S.; Boutoille, D.; Brunet, C.; Jovelin, T.; Hall, N.; Bernaud, C.; Morineau, P.; Reliquet, V.; Aubry, O.; Point, P.; Besnier, M.; Larmet, L.; Hüe, H.; Pineau, S.; André-Garnier, E.; Rodallec, A.; Choisy, Ph.; Vandame, S.; Huleux, Th.; Ajana, F.; Alcaraz, I.; Baclet, V.; Huleux, T.H.; Melliez, H.; Viget, N.; Valette, M.; Aissi, E.; Allienne, Ch.; Meybeck, A.; Riff, B.; Bani-Sadr, F.; Rouger, C.; Berger, J.L.; N'Guyen, Y.; Lambert, D.; Kmiec, I.; Hentzien, M.; Lebrun, D.; Migault, C.; Rey, D.; Batard, M.L.; Bernard-Henry, C.; Cheneau, C.; de Mautort, E.; Fischer, P.; Partisani, M.; Priester, M.; Lucht, F.; Frésard, A.; Botelho-Nevers, E.; Gagneux-Brunon, A.; Cazorla, C.; Guglielminotti, C.; Daoud, F.; Lutz, M.F.; Jacomet, C.; Laurichesse, H.; Lesens, O.; Vidal, M.; Mrozek, N.; Corbin, V.; Aumeran, C.; Baud, O.; Casanova, S.; Coban, D.; Hustache-Mathieu, L.; Thiebaut-Drobacheff, M.C.; Foltzer, A.; Gendrin, V.; Bozon, F.; Chirouze, C.; Abel, S.; Cabié, A.; Césaire, R.; Santos, G. Dos; Fagour, L.; Najioullah, F.; Ouka, M.; Pierre-François, S.; Pircher, M.; Rozé, B.; Hoen, B.; Ouissa, R.; Lamaury, I.; Pradat, Pierre; Pugliese, Pascal; Poizot-Martin, Isabelle; Valantin, Marc-Antoine; Cuzin, Lise; Reynes, Jacques; Billaud, Eric; Huleux, Thomas; Bani-Sadr, Firouze; Rey, David; Frésard, Anne; Jacomet, Christine; Duvivier, Claudine; Cheret, Antoine; Hustache-Mathieu, Laurent; Hoen, Bruno; Cabié, André; Cotte, Laurent;
• Is Part Of: Journal of infection. Volume 75:Issue 3(2017)
• Page Start: 234
• Page End: 241
• Publication Date: 2017-09
• Subjects: HIV -- HCV -- Coinfection -- Treatment uptake -- Epidemiology -- Direct acting antiviral agent -- DAA; Infection -- Periodicals; Bacterial Infections -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.905
• DOI: 10.1016/j.jinf.2017.05.008
• Languages: English
• ISSNs: 0163-4453

Abstract

Summary: Objectives: Direct-Acting Antivirals (DAAs) opened a new era in HCV treatment. We report the impact of HCV treatment in French HIV-HCV coinfected patients. Methods: All HIV-HCV patients from the Dat'AIDS cohort followed between 2012 and 2015 were included. HCV status was defined yearly as naive, spontaneous cure, sustained virological response (SVR12), failure or reinfection. Results: Among 32, 945 HIV-infected patients, 15.2% were positive for anti-HCV antibodies. From 2012 to 2015, HCV incidence rate increased from 0.35%PY to 0.69%PY in MSM, while median incidence was 0.08%PY in other patients. Median reinfection rate was 2.56%PY in MSM and 0.22%PY in other patients. HCV treatment initiation rate rose from 8.2% in 2012 to 29.6% (48.0% in pre-treated patients vs 22.6% in naïve patients). SVR12 rate increased from 68.7% to 95.2%. By the end of 2015, 62.7% of the patients were cured either spontaneously or following SVR. Conclusions: HCV treatment dramatically increased in HIV-HCV patients in France from 2012 to 2015 resulting in HCV cure in nearly two-thirds of the patients in this cohort. Combined with a declining HCV prevalence, the prevalence of active HCV infection among HIV patients will drastically decrease in the forthcoming years. Highlights: The Dat'AIDS cohort covers about 25% of HIV-infected patients in France. DAA are highly effective in a real world cohort of HIV-HCV coinfected patients. In 2015, HCV treatment initiation rate was 29% in HIV-HCV patients in France. By the end of 2015, 63% of patients were cured either spontaneously or following SVR.